Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06902584
Completed Observational

North American Comfilcon A Clinical Study

NCT06902584 · tracked via the Priya Life Science USA tracker
Sponsor
CooperVision International Limited (CVIL)
Phase
Observational
Started
2025-01-31
Last updated
2026-11-04

Condition(s) studied

AstigmatismPresbyopiaAmetropia

Investigational drug(s) / intervention(s)

comfilcon A Sphere lenscomfilcon A Toric lenscomfilcon A Multifocal lenscomfilcon A Multifocal Toric lenscomfilcon A Energys lens

comfilcon A Sphere lens: 2 hours of wear

comfilcon A Toric lens: 2 hours of wear

comfilcon A Multifocal lens: 2 hours of wear

comfilcon A Multifocal Toric lens: 2 hours of wear

comfilcon A Energys lens: 2 hours of wear

Study summary

The main objective of this study is to demonstrate acceptable safety and effectiveness (performance) of comfilcon A Sphere, Toric, Multifocal, Toric Multifocal and Energys lenses, when used in the general population.

Eligibility

Sex
ALL
Min age
8 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age 8 to 75 years (inclusive). 2. Current wearer of the Comfilcon A sphere, toric, multifocal, toric multifocal or Energys contact lens for at least 12 months. 3. At least occasional overnight wear in the last 12 months. Exclusion Criteria: 1\. Current participation in a contact lens or contact lens care product clinical trial.

Primary outcome measure(s)

  • Visual Performance (Visual Acuity) — At the end of 2 hours of wear
    Visual Performance will be measured using logMAR * High contrast, high illumination distance VA * High contrast, high illumination near VA
  • Incidence of contact lens-related adverse events — At the end of 2 hours of wear
    Incidence of contact lens-related adverse events will be recorded from subjects

Trial sites (4)

FacilityCityRegionStatus
University of Berkeley Berkeley California
ProCare Vision Center Granville Ohio
Nittany Eye Associates College Pennsylvania
Drs. McIntyre, Garza, Avila and Jurica, Optometrists Corpus Christi Texas

More CooperVision International Limited (CVIL) trials in the USA

Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter Recruiting
Clinical Performance and Outcomes After Toric Lens Transition Starting soon
Evaluation of Two Monthly Silicone Hydrogel Multifocal Toric in Soft Contact Lens Wearers Starting soon

Other trials for the same condition

Observational Study - TA- 2025-1 Enrolling by invitation
Clareon TruPlus Study Recruiting
Phase III Presbyopia Correction Using the VIS Opti-K™ System Recruiting
Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter Recruiting
The VIS Opti-K Low Vision Aid Device Provides Vision Improvement. Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06902584 on ClinicalTrials.gov ↗ ← All trials in the USA